[Survival and recurrence of endometrial adenocarcinoma]. / Sopravvivenza e recidive dell'adenocarcinoma dell'endometrio.

444 endometrial carcinomas were retrospectively reviewed. Disease-free survival (DFS) was 83.6% at five years and 80.5% at ten years. 349 T1 cancers were treated by TAH-BSO and post-operative irradiation; 22.6% of them were over-staged. DFS ranged from 100% to 91% in 270 low-risk T1 patients, dropping to 84% in intermediate risk patients and to 44% in high-risk patients. DFS was 93% and 66% in the patients overstaged as pT2 and pT3, respectively; it was 82% for ovarian spread and 45% for pelvic peritoneum/parametrium invasion. T2-T3 patients were treated with preoperative irradiation and bilateral hysterectomy. DFS was 90.5% vs. 72.2% and 2/2 vs. 3/7 when the lesion was understaged. The results of irradiation were similar to literature data, but 53% of patients (all in poor general conditions and/or very old) died from associated diseases. Relapses were observed in 13.6% of cases (62/444 patients); 29 (6%) were local recurrences and 33 (7.6%) were distant metastases, which correlated well with recurrences and 33 (7.6%) were distant metastases, which correlated well with risk factors. Severe complication (G3) were observed in 6.3% of cases.

[The use of aminoglutethimide in the treatment of metastatic breast cancer]. / L'impiego dell'aminoglutetimide nel trattamento del carcinoma mammario metastatico.

It has been demonstrated that AG inhibits the peripheric conversion of androstenedione into estrogens and produces an adrenal suppression, equivalent to surgical adrenalectomy. As breast cancer is responsive to hormonal therapy, AG has been used in the treatment of metastatic breast cancer. Since 1984, at I Clinica Ostetrica e Ginecologica of University of Torino, 48 patients with advanced breast cancer, previously treated with chemotherapy and hormonotherapy, have been given AG 1 g/day and hydrocortisone 40 mg/day. Six patients (12%) obtained CR, nine (19%) a PR, eleven (23%) a SD, twenty two (46%) a PD. The efficacy of AG has been evaluated as related to the following prognostic factors: menopausal status, hormone receptors, disease free interval, age, prior tamoxifen exposure. This study shows that bone involvement is the most responsive localization to AG. In conclusion AG is still an effective therapeutic choice in metastatic breast cancer treatment.